Evaluation of the Potential for Drug-Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data.

Bergagnini-Kolev, Mackenzie; Kane, Katie; Templeton, Ian E; Curran, Aidan K

Bergagnini-Kolev, Mackenzie; Kane, Katie; Templeton, Ian E; Curran, Aidan K.

Affiliation

Bergagnini-Kolev M; Simcyp Ltd (Division of Certara), Seattle, Washington, USA.
Kane K; Pulmatrix, Inc, 36 Crosby Drive, Suite 100, Bedford, MA, 01730, USA.
Templeton IE; Simcyp Ltd (Division of Certara), Seattle, Washington, USA.
Curran AK; Pulmatrix, Inc, 36 Crosby Drive, Suite 100, Bedford, MA, 01730, USA. caintebio@gmail.com.

AAPS J ; 25(4): 62, 2023 06 21.

Article in En | MEDLINE | ID: mdl-37344751

Subject(s)

Itraconazole; Midazolam; Humans; Itraconazole/pharmacokinetics; Midazolam/pharmacokinetics; Models, Biological; Cytochrome P-450 CYP3A Inhibitors/pharmacokinetics; Cytochrome P-450 CYP3A; Drug Interactions

Key words

allergic bronchopulmonary aspergillosis; cystic fibrosis; drug-drug interactions; itraconazole; pharmacokinetics; physiologically based pharmacokinetics

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Midazolam / Itraconazole Type of study: Prognostic_studies Limits: Humans Language: En Journal: AAPS J Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2023 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google